Aducanumab Approval: Opening the Floodgates for a New Era of…
With the US FDA’s controversial recent decision to approve Biogen and Eisai’s aducanumab – the first approval for a new Alzheimer’s disease…
Tagged with Biogen
If the “Primary Endpoint” in an Alzheimer’s…
Taking the example of music's effect on Alzheimer's disease patients, John G Singer makes the case for a more holistic approach to healthcare;…
Katharina Gasser – Managing Director, Biogen Switzerland
Biogen Switzerland’s Dr med Katharina Gasser outlines how her affiliate navigated the COVID-19 pandemic from an organisational and communication…
Antonella Santuccione Chadha – CEO pro-bono, Women’s…
Antonella Santuccione Chadha*, Head of Stakeholder Engagement for Alzheimer’s disease at Biogen and co-founder and CEO of the Women’s Brain…
Swiss Pharma: Staying the Course
This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss…
Biogen’s Swiss Head on Benefits of Diverse Experience…
A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before…
What Three Pharma Leaders Want to Share About Switzerland
PharmaBoardroom highlights three of the most enterprising and dynamic pharma affiliate country managers working in Switzerland today and their…
Aducanumab edges closer to Potential Approval: Next up, the…
In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory…
Moving the Needle on Gender Diversity in Swiss Pharma Leadership
While Switzerland has Europe's second-highest proportion of women in the workforce, it trails global standards on gender diversity in boardrooms and…
Katharina Gasser – Managing Director, Biogen Switzerland…
Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why…
Market Access in Switzerland: Reimbursement Delays for 76% of New…
Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to…
Aducanumab: On the Regulatory Home Stretch in the USA
In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr…
